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Novel adipokines, high molecular weight
adiponectin and resistin, are associated with
outcomes following lower extremity
revascularization with autogenous vein
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Allen Hamdan, MD,b Joseph D. Raffetto, MD,c Mark A. Creager, MD,d and
Michael S. Conte, MD,a San Francisco, Calif; Boston, Mass; and West Roxbury, Mass
Objective: A significant portion of patients undergoing lower extremity bypass surgery (LEB) for peripheral arterial
disease (PAD) will have cardiovascular or graft-related events. It has been previously demonstrated that systemic
inflammation is associated with PAD and its clinical outcomes. We hypothesized that serum biomarkers of insulin
resistance and inflammation would identify a subgroup at elevated risk for graft failure, limb loss, and mortality.
Methods: This was a prospective longitudinal study of patients (n  225) undergoing LEB using autogenous vein. Baseline
blood samples were obtained prior to surgery in the fasting state. High-sensitivity C-reactive protein (hsCRP) and the
adipokines resistin and high-molecular weight adiponectin (HMWA) were measured by enzyme-linked immunosorbent assay
(ELISA). Median follow-up was 893 days. The major endpoints of primary patency (PP) and amputation-free survival (AFS)
were examined using multivariable methods. Endpoints were screened against biomarkers and patient characteristics for
univariate associations. Promising explanatory variables (P< .1) were included inmultivariable Cox proportional hazardmodels.
Results: The mean age of subjects was 67.6 years; 71.6% were male and 87.1% were Caucasian. One hundred thirty-three
(59.1%) subjects underwent bypass for critical limb ischemia (CLI) and 73 (32.4%) had tissue loss. Patients with CLI and
diabetes demonstrated elevated resistin and hsCRP levels. HMWA levels correlated with CLI and with a measure of
insulin resistance (HOMA-IR) but not with clinical diabetes. Baseline biomarkers were higher in those presenting with
tissue loss and in patients with postoperative events (mortality, limb loss). After multivariable analysis (including CLI,
diabetes, age, estimated glomerular filtration rate [eGFR], adiponectin, resistin, and CRP), resistin (hazard ratio [HR]
1.75, 95% confidence interval [CI], 1.07-2.85; P  .025) and CRP (HR 2.39, 95% CI, 1.30-4.39; P  .005) were
independently predictive of reduced AFS. However, only resistin maintained its significance when restricted to the
diabetic cohort (HR 2.10, 95% CI, 1.10-3.99; P  .025). Higher levels of HMWA were found to be associated with
primary graft patency (HR 0.73 for graft failure; 95% CI, 0.55 to 0.97; P  .031) in a multivariable model adjusting for
diabetes, CRP, African-American race, CLI, high-risk conduits, and redo bypass procedures.
Conclusion: These findings suggest that serum biomarkers of insulin resistance and inflammation may be predictive of
clinical outcomes following LEB. Improving the systemic milieu of insulin resistance and inflammation in these high-risk
patients may lead to reduced morbidity and mortality. ( J Vasc Surg 2010;51:1152-9.)The incidence of peripheral artery disease (PAD), a
manifestation of atherosclerosis, is widespread and is only
expected to increase as the aging population grows and the
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Patients undergoing lower extremity bypass (LEB) surgery for
severe PAD demonstrate a profound inflammatory pheno-
type, based on plasma high-sensitive C-reactive protein
(hsCRP) concentrations.1 Although inflammatory biomark-
ers such as hsCRP have been linked to adverse cardiovascular
events such as myocardial infarction, death, and stroke, in
PAD patients,2 their specific relationship to the outcomes of
surgical revascularization are not clearly established.1 LEB
using autogenous vein is commonly employed and often
effective; however, factors responsible for the variability in
outcome are poorly understood.3 For example, conventional
cardiovascular risk factors such as hypertension, hypercholes-
terolemia, andDM are not predictive for lower extremity vein
graft failure.3 Specifically, DM, characterized by insulin resis-
tance, central obesity, and inflammation, adversely affects
morbidity and mortality following vascular surgery, but,
counterintuitively, is not directly associated with lower ex-
tremity vein graft failure.3
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tion and insulin resistance, with respect to outcomes fol-
lowing lower extremity revascularization, have been lacking
even though both are linked to atherosclerosis. These in-
vestigations seem especially pertinent given the burgeoning
epidemic of obesity and DM in Western populations.4 The
relationship between central obesity and adverse cardiovas-
cular outcomes is well known.5 We have now come to
recognize that differentiated adipose tissue, far from being
a simple fat depot, can function as an endocrine organ.6 As
adipocytes enlarge during obesity, macrophages are re-
cruited and proinflammatory cytokines are produced.7 This
may lead to vascular inflammation, endothelial dysfunction,
and neointimal thickening, further promoting atheroscle-
rotic disease. In particular, two novel adipokines, adiponec-
tin and resistin, have garnered interest for their potential
roles in inflammation and insulin resistance. Adiponectin, a
relatively abundant protein found in adult adipocytes from
which it is mostly made, has many isoforms of which the
high-molecular weight adiponectin (HMWA) has been
found to be the most sensitive as a clinically useful biomar-
ker in cardiovascular disease.8-10 In general, adiponectin
can be thought of as a vascular protective hormone having
anti-atherogenic and anti-diabetic effects.11 By contrast,
considerably less clinical information is available for resistin.
As its name implies, resistin has been shown to provide a
link between obesity and diabetes in mice by impairing
glucose tolerance and antagonizing insulin.12 In humans,
however, its role is not as straightforward, although it has
been implicated in inflammatory processes.13
In this study, we sought to assess the association of
these novel adipokines with the clinical outcomes of
amputation-free survival (AFS) and vein graft patency in
patients undergoing LEB surgery with autogenous vein.
METHODS
Study design and population. This was a National
Institutes of Health-sponsored prospective cohort study
examining the relationship of metabolic factors, inflamma-
tion, and outcomes following LEB with autogenous vein.
The study was undertaken at three Boston teaching hospi-
tals. All participating institutions underwent independent
review of the study and received approval from the Institu-
tional Review Board. Each patient provided written in-
formed consent. Enrollment began in February 2004 and
ended in May 2008.
Details of patient selection/inclusion and exclusion
criteria have been published previously.1,14 In brief, sub-
jects were excluded if they were treated with a prosthetic or
other nonautolgous vein material. Other exclusion criteria
included history of diagnosed hypercoagulable state, evi-
dence of active infection, and other concurrent significant
illness within 30 days (ie, myocardial infarction, stroke, or
other major surgery). While patients with small ulcers or
small areas of dry gangrene were accepted into the study,
deep space infections of the foot, those with large areas of
ulceration, or ulceration or gangrene requiring operativedebridement were excluded from participation. In total,
225 patients were enrolled.
Blood processing and assay measurements of
biomarkers. Plasma was collected with the patient in the
fasting state on the morning of the bypass procedure.
Blood was collected into EDTA and citrate vacutainer
tubes and immediately iced. Tubes were spun at 3000 rpm
for 20 minutes at 4°C in a refrigerated centrifuge. All
samples were stored in a 80°C freezer until the time of
analysis. All analysis was conducted in batch at a core lab to
avoid variation. The hsCRP level was determined using an
immunoturbidimetric assay on a Hitachi 917 analyzer
(Roche-Diagnostics, Indianapolis, Ind) using reagents and
calibrators from Denka Seiken (Niigata, Japan). This assay
has a sensitivity of 0.03 mg/L, and the day-to-day varia-
tions of the assay at differing concentrations are less than
3%. Adiponectin was analyzed using an enzyme-linked
immunosorbent assay (ELISA) method from ALPCO Di-
agnostics Inc. (Salem, NH). The day-to-day variation of
the assay at various concentrations of adiponectin is less
than 15% and has a sensitivity of 0.386 g/mL. Resistin
was analyzed using an ELISA assay (R & D Systems,
Minneapolis, Minn), and it has a sensitivity of 0.26 ng/mL.
Insulin, glucose, lipids, hemoglobin A1c (hgbA1c),
and creatinine were all analyzed at the clinical laboratory of
each site using standard techniques.
The homeostasismodel of insulin resistance (HOMA-IR)
was calculated from the product of (insulin [microunits/mL]
and glucose [mmoles/L]) divided by 22.5. TheHOMA-IR
correlates well with insulin sensitivity derived from the
glucose clamp technique, the gold standard measure of
insulin sensitivity.15 Subjects taking insulin (n  79) were
excluded from HOMA-IR measurements.
TheModificationofDiet inRenalDisease Study equation
was used to estimate glomerular filtration rate (eGFR) from
serum creatinine (SCr): eGFR (mL · min1 · 1.73 m2) 
175 · (SCr)1.154 · (age)0.203 · (0.742 if female) · (1.210 if
black).
Operative procedure. Patients underwent lower ex-
tremity bypass surgery utilizing autogenous vein under the
direction of the attending surgeon. Ipsilateral great saphe-
nous vein was the conduit of first choice but, in its absence,
contralateral great saphenous or arm vein was used. Details
of the operative procedure were recorded, as well as any
adjunctive procedures and the results of completion stud-
ies. It is the standard practice at all participating centers to
perform completion duplex ultrasound and/or completion
angiography. Any flow disturbances or intrinsic vein disease
would be identified during this time.
Patients were monitored for postoperative complica-
tions during their initial hospitalization and subsequent
visits. All patients enrolled were followed postoperatively
by the attending vascular surgeon and underwent duplex
ultrasound surveillance at 1, 3, 6, 9, and 12 months. The
duplex ultrasound was performed in an Intersocietal Com-
mission for the Accreditation of Vascular Laboratories
(ICAVL) vascular laboratory at each of the three enrolling
facilities. After 12 months, the follow-up visits occurred
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left to the discretion of the operating surgeon. All patients
underwent a complete vascular examination at these
follow-up assessments, and any clinical or graft-related
events were recorded. In addition to the scheduled ap-
pointments, research coordinators from each participating
site monitored events and outcomes through contact with
the patients, their primary care providers, and the electronic
medical record. Any patients without contact with study
personnel for 18 months were considered lost to follow-up
and censored from their last point of contact.
Clinical and endpoint definitions. Race, ethnicity,
and gender were assessed by self-report. Subjects were
considered to have hypertension if they were taking pre-
scriptionmedications for hypertension, if they had a systolic
blood pressure 140 mm Hg or a diastolic blood pressure
90 mm Hg. A diagnosis of hypercholesterolemia was
present if they were taking prescription medications for
cholesterol or if they self-reported a prior diagnosis. Sub-
jects were considered to have DM if the subject was taking
prescription medications (oral or insulin) for diabetes, or if
they self-reported a prior diagnosis. Active smoking was
determined by self-report (a positive answer to the ques-
tion, “Do you now smoke cigarettes?”). Former smokers
were defined as individuals who had smokedmore than 100
cigarettes in their life but had not in 30 days, and never
smokers were defined as persons who had never smoked.
Body mass index (BMI) was calculated as the quotient of
weight divided by height in (kg/m2).
Primary patency was defined according to accepted
published clinical reporting standards.16 Loss of primary
patency includes any graft revision (patch angioplasty, in-
terposition graft, or balloon angioplasty) based on detec-
tion of vein graft stenosis by duplex ultrasound or docu-
mentation of graft stenosis by an imaging procedure in the
appropriate clinical setting. Loss of primary patency was
also noted if there was documentation of occlusion of the
vein graft without revision. Amputation was defined as any
supramalleolar amputation of the index leg, and a loss of
amputation-free survival was defined as either amputation
or death.
Statistical analysis. Baseline characteristics and bi-
omarker values are presented as mean SD or median and
interquartile (IQR) range depending on the normality of
their distribution. Proportions between groups were com-
pared with chi-squared test. Correlations were assessed
with Pearson’s correlation coefficients on log-normalized
marker values. Univariate differences in plasma levels of
markers between subgroups of patients were analyzed
with one-way nonparametric Wilcoxon rank-sum (Mann-
Whitney U) tests. Multivariable Cox proportional hazard
modeling was performed on clinical survival outcomes.
Log-transformed biomarker values were used as predictors
along with other clinical variables having univariate associ-
ations with P values  0.10. For all time-to-event analysis,
subjects not experiencing an adverse event were censored at
the last known contact. Statistical analyses were performedon Stata/SE 10.0 (StataCorp, College Station, Tex) and
with SAS 9.2 (SAS Institute, Cary, NC).
RESULTS
Population demographics and bypass graft
characteristics. The demographic summary of the study
population is presented in Table I. There were 117 (52%)
patients with DM, of which 79 were taking insulin and 52
were taking an oral hypoglycemic agent (14 were taking
both insulin and an oral hypoglycemic agent). Chronic
kidney disease (CKD), defined as the presence of the esti-
mated glomerular filtration rate (eGFR) of  60
mL · min1 · 1.73 m2, was present in 74 (33%) patients,
and 10 were on hemodialysis. The indication for bypass
surgery was critical limb ischemia (CLI) in 133 (59.1%)
patients, 73 of which had distal tissue loss (32.4%). Twenty-
two of the patients had a previous failed ipsilateral bypass
graft. A single-segment great saphenous vein was used for
construction of the bypass in 190 (84.4%) of the subjects,
while composite constructions of great saphenous vein or
arm vein were used in the remainder. The mean follow-up
from LEB was 925 days (median, 893 days; IQR, 539-
1315 days). No surviving individual was followed less than
365 days.
Baseline metabolic and inflammatory biomarkers.
Biomarkers of insulin resistance and inflammation, and
other selected laboratory values, are presented in Table II.
Baselinemarkers were strongly associated with PAD clinical
severity. Both HMWA (2.2 vs 1.6 g/mL, P .0206) and
resistin (15.1 vs 10.2 ng/mL, P  .00001) were higher in
patients presenting with CLI vs claudication. There were
also marked differences in the metabolic and inflammatory
Table I. Patient demographics
Demographic
Age (mean  SD) 67.6  10.9
Male (%) 161 (71.6%)
White (%) 196 (87.1%)
Length of follow-up (median  IQR) 893 days (539-1315
days)
Comorbidities
Hypertension (%) 190 (84.4%)
Coronary artery disease (%) 118 (52.4%)
Diabetes mellitus (%) 117 (52%)
Body mass index (median  IQR) 27.4 (24.1-31.2)
Hematocrit (median  IQR) 36 (31.5-39.3)
Critical limb ischemia (%) 133 (59.1%)
Tissue loss (%) 73 (32.4%)
Estimated glomerular filtration rate
(median  IQR) 77.1 (52.3-93.3)
Dialysis (%) 10 (4.4%)
Medications
Statins (%) 174 (77.3%)
Insulin (%) 79 (35.1%)
Oral agent (%) 52 (23.1%)
Graft characteristics
Redo bypass (%) 22 (9.8%)
Single-segment great saphenous vein (%) 190 (84.4%)
IQR, Interquartile range.profile of subjects with clinical diabetes. Patients with DM
was
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A1c (hgbA1c); and lower hematocrit, eGFR, total choles-
terol, and high-density lipoprotein (HDL; all P  .05).
Interestingly, both HMWA values (1.9 vs 2.0 g/mL, P
.8807) and HOMA-IR scores (1.7 vs 2.1, P .4161) were
not different between the diabetic and nondiabetic sub-
jects, suggesting the underlying prevalence of insulin resis-
tance in the overall study population.
A summary of correlations among the biomarkers is
presented in Table III. HMWA was positively correlated
with HDL cholesterol, and more weakly with hsCRP.
There was an inverse correlation of HMWA and HOMA-
IR, indicating the association between HMWA and insulin
resistance in this patient population (r  -0.2508, P 
.0165; Fig 1a).
Resistin was positively correlated with hsCRP (r 
0.40, P  .0001; Fig 1b). Resistin was independently
associated with CLI as an indication for bypass after con-
trolling for hsCRP and DM (odds ratio 2.20; 1.30-3.71;
Table II. Patient inflammatory and metabolic profile
Markers
Total cohort
(n  225)
Non-DM
(n  108) (
HMWA g/mL 2.0 (1.1-3.4) 2.0 (1.1-3.4) 1.9
Resistin ng/mL 12.9 (8.6-19.9) 11.5 (8.2-16.5) 15.2
hsCRP mg/L 3.0 (1.3-12.3) 2.6 (1.2-5.5) 3.3
Total cholesterol,
mg/dL 125 (105-145.5) 127 (109-156) 124
HDL, mg/dL 32.0 (28-39) 33.8 (29-41) 31.0
LDL, mg/dL 62.0 (44-78) 63.0 (46-82) 62.0
Triglycerides,
mg/dL 121 (87-173) 121 (87-179) 120
HgbA1c % 6.3 (5.7-7.3) 5.8 (5.5-6.1) 7.0
eGFR,
mL · min1 ·
1.73 m2 77.1 (52.3-93.3) 84.9 (63.8-104.6) 66.9
BMI, kg/m2 27.4 (24.1-31.2) 26.5 (23.6-29.7) 28.4
HOMA-IR* 1.8 (0.8-3.5) 1.7 (0.8-3.0) 2.1
Albumin 3.6 (3.3-3.9) 3.7 (3.7-4.1) 3.6
BMI, Bodymass index;CLI, critical limb ischemia;DM, diabetes mellitus; eG
high-molecular weight adiponectin; HOMA-IR, homeostasis model of insu
Values presented are median (interquartile range; IQR). Significance testing
*HOMA-IR was only assessed in 18 subjects within the DM cohort.
Table III. Correlations between inflammatory and metab
HMWA
HMWA, g/mL
Resistin, ng/mL 0.280, .0001
hsCRP, mg/L 0.197, 0.0040
Total cholesterol, mg/dL 0.002, 0.981
HDL, mg/dL 0.301, .0001
LDL, mg/dL 0.042, 0.5550
Triglycerides, mg/dL 0.101, 0.1490
HgbA1c % 0.089, 0.2650
HOMA-IR 0.251, 0.0165
BMI 0.141, 0.0390
BMI, Body mass index; HDL, high-density lipoprotein; HMWA, high-mo
hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein.P  .003).Low HMWA levels are associated with loss of vein
graft primary patency. There were 78 (34.7%) bypass
grafts that met the definition of loss of primary patency.
The 2-year primary patency rate was 61.4  3.6% for the
entire cohort. After adjusting for high-risk conduits (com-
posite and arm vein grafts), redo surgery, CLI, elevated
hsCRP (5 mg/L), the presence of DM, and African-
American (AA) race, HMWA (HR 0.731, 95% CI, 0.551-
0.972; P  .031) and AA race (HR 2.70, 95% CI, 1.39-
5.24; P  .003) were the only significant risk factors
associated with loss of primary patency (Fig 2).
High resistin levels are associated with reduced
amputation-free survival. There were 60 (26.7%) sub-
jects who either died or underwent amputation during the
follow-up period. The 2-year AFS in the overall cohort was
79.3  2.8%. Both HMWA and resistin, in addition to
hsCRP, age, eGFR, DM, and CLI, were associated with
AFS on univariate testing. However, only resistin (HR
1.75; 1.07-2.85, P  .025; Fig 3) and hsCRP (HR 2.39;
17) P value
Claudicants
(n  92)
CLI
(n  133) P value
-3.4) 0.8807 1.6 (1.1-2.7) 2.2 (1.1-4.2) .0206
-22.7) 0.0090 10.2 (7.7-15.5) 15.1 (10.4-23.6) .0001
-16.7) 0.0193 1.8 (0.9-4.0) 5.5 (1.7-21.6) .0001
-139) 0.0460 131 (115-158) 121 (98-139) .0006
37) 0.0151 33 (28-40.4) 32 (27-37) .1403
78) 0.4034 67.4 (52.2-85) 58 (41-75) .0032
171) 0.7154 115 (88.5-175.5) 126 (86-171) .7124
-8.0) .0001 6.3 (5.7-7.1) 6.5 (5.8-7.3) .3825
9-87.3) 0.0002 87.3 (66.3-103.9) 68.8 (41.5-86.9) .0001
4-32.0) 0.0147 28 (24.8-31.2) 27.1 (23.7-30.9) .2196
-3.7) 0.4161 1.9 (0.8-3.7) 1.6 (0.7-2.8) .3002
-3.8) 0.0175 3.7 (3.5-4.0) 3.5 (3.1-3.9) .0079
stimated glomerular filtration rate;HDL, high-density lipoprotein;HMWA,
istance; LDL, low-density lipoprotein.
done with Wilcoxon rank-sum tests.
iomarkers
Resistin hsCRP
0.281, .0001 0.197, 0.0040
0.403, .0001
0.403, .0001
0.189, 0.0065 0.271, .0001
0.124, 0.0760 0.105, 0.1330
0.187, 0.0080 0.258, 0.0002
0.247, 0.0003 0.091, 0.1930
0.022, 0.7850 0.099, 0.2160
0.104, 0.3250 0.028, 0.7890
0.042, 0.5440 0.012, 0.8570
weight adiponectin; HOMA-IR, homeostasis model of insulin resistance;DM
n  1
(1.1
(8.8
(1.5
(103
(27-
(43-
(87-
(6.3
(41.
(24.
(1.1
(3.1
FR, e
lin resolic b
lecular1.30-4.39; P  .005) were independently associated with
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appeared to have additive ability to discriminate AFS out-
comes. For example, in patients with hsCRP5 mg/L and
in the lowest tertile of resistin, there were only 3 of 55
(5.5%) patients who either died or underwent major ampu-
tation, as compared with 28 of 43 (65.1%) for individuals
with both hsCRP 5 mg/L and resistin values in the
highest tertile. When restricting the cohort to only subjects
with DM, the effect size of hsCRP was attenuated, leaving
only resistin as an independent predictor of AFS (HR 2.10;
1.100-3.993, P  .025).
DISCUSSION
The present study demonstrates that the adipokines,
HMWA, and resistin further characterize the inflammatory
phenotype of LEB patients and are associated with clinical
outcomes. Levels of resistin were markedly elevated and
strongly correlated with hsCRP; however, resistin was in-
dependent of, and added predictive value to, hsCRP with
respect to AFS. Importantly, resistin was the only baseline
variable that maintained its predictive ability for AFS within
the DM-restricted cohort. By contrast, plasma HMWA
concentrations were notably low in patients undergoing
Fig 1. (a) High molecular weight adiponectin (HMWA) is neg-
atively correlated with insulin resistance as assessed by homeostasis
model of insulin resistance (HOMA-IR), while (b) resistin is
positively associated with inflammation as assessed by high sensi-
tivity C-reactive protein (hsCRP). All values represent natural
logarithm transformations.LEB for advanced PAD in comparison to patients withcoronary artery disease,17 suggesting the breadth of the
insulin-resistant phenotype in this population. A striking
finding was the association of lower levels of HMWA with
increased risk for vein graft failure. To our knowledge, this
represents the first report of a circulating biomarker that
may be associated with a protective effect on vein graft
primary patency.
Adiponectin exerts its biological action on the vascular
wall through one of two receptors that have been found in
the liver and on human endothelial and smooth muscle
cells.18 Its biological activity is dependent, in part, on its
plasma oligerimization state, with theHMWA species being
the most biologically sensitive and relevant to clinical out-
comes.19 Low levels of adiponectin have been associated with
impaired vascular reactivity,20 symptomatic atherosclerotic
peripheral arterial disease (PAD),21 and coronary artery dis-
ease (CAD). Similar to previous investigations, HMWA was
significantly correlated with insulin resistance in our study
(estimated by HOMA-IR).
The seemingly paradoxical finding that HMWA levels
were higher in patients with CLI than in those with clau-
dication merits discussion. Several studies have demon-
strated that the beneficial effects of adiponectin are not a
straightforward dose-response relationship, indicating that
other factors are involved. For example, higher adiponectin
values were associated with increased mortality in patients
with congestive heart failure (CHF).22 This observation
may be explained, in part, by a positive association of
adiponectin and N-terminal pro-B-type natriuretic peptide
(NT-proBNP) in CHF patients.22 It has recently been
shown that NT-proBNP is associated with adverse cardio-
vascular events and mortality in patients undergoing vascu-
lar surgery.23 Another intriguing possibility is that higher
HMWA in some patients might be indicative of a wasting
process.24 It has been shown that circulating adiponectin
levels are higher in patients undergoing weight loss.25
Therefore, patients with advanced CHF or severe CLI may
have higher baseline energy expenditure.26 This is consis-
tent with the present investigation, as patients with CLI
had significantly lower total cholesterol, lower albumin,
and lower body weight, suggesting a relative wasting state
over claudication counterparts. A recent study by Komei et
al reported that total plasma adiponectin levels were asso-
ciated with decreased survival following LEB surgery.27
However, several noteworthy differences exist from the
present study.While there was a weak univariate association
of HMWAwith decreased AFS in the present investigation,
this result was attenuated after controlling for disease sever-
ity and inflammation. In addition, we elected to measure
HMWA rather than total adiponectin, as several previous
investigations suggest that this is the more biologically
active species and most closely correlates with clinical out-
comes. Finally, there were only 12 deaths in the study by
Komei et al, which significantly limits the ability to con-
struct reliable event-driven models, and therefore limits the
conclusions.27
Another noteworthy finding of the present investiga-
tion was that the low-density lipoprotein (LDL) fraction of
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even among subjects not taking a statin (mean LDL on
statin, 60.9 mg/dL; mean LDL not on statin, 74.5 mg/
dL). These values are well below the National Cholesterol
Education Program Adult Treatment Plan III recommen-
dation of targeting LDL to below 100 mg/dL with an
option to decrease LDL to 70 mg/dL in patients with
established cardiovascular disease.28 Despite this, the me-
dian hsCRP was 3.0 mg/L, which places these patients in
the American Heart Association’s highest risk category.29
Therefore, this combination of low LDL cholesterol and
high levels of inflammatory biomarkers potentially makes
this an ideal population to test the hypothesis that lowering
inflammation per se will be efficacious in the secondary
prevention of cardiovascular events as well as vein graft-
related outcomes.
In this investigation, resistin was independently associ-
ated with the clinical outcome, AFS, after controlling for
hsCRP and other comorbidities. Further, in the diabetic-
restricted cohort, resistin was the only significant predictor of
HR
HMWA (ln) 0.73
DM 1.46
hsCRP >5 mg/L 1.55
redo bypass 1.71
AA race 2.70
CLI 1.66
Non-SSGSV 1.25
Fig 2. Multivariable analysis of primary graft patency in
with autogenous vein. After controlling for diabetes m
mg/L), redo bypass, African-American race (AA), cr
saphenous vein (non-ssgsv), only high molecular weight a
patency.AFS after the effect of high hsCRP and CLI were attenuated.Therefore, we believe that plasma resistin values represent a
potentially usefulmarker for adverse outcomes followingLEB
surgery, particularly in patients with DM.
Another novel finding of the present study is that
resistin was independently associated with CLI after con-
trolling for other inflammatory markers and DM. How
does resistin contribute to the inflammatory state of the
PAD patient? Unlike rodents, where high levels of resistin
mRNA transcripts are found in adipose tissue, the majority
of resistin in humans can be found in inflammatory and
mononuclear cells.30 Thus, resistin appears to be produced
in the periphery, unlike the acute phase reactant, hsCRP,
which is predominantly produced in the liver.31
It should also be emphasized that the values of resistin
observed in this patient population were extremely high. In
the Study of Inherited Risk of Coronary Atherosclerosis
(SIRCA), a study of apparently asymptomatic middle-aged
men and women, the median resistin values were about 5.6
ng/mL, which compares with patients with DM, where the
resistin levels were about 5.8 ng/mL.32 This is in stark
95% CI p-value
0.55 - 0.97) 0.031
0.89 - 2.38) 0.130
0.94 - 2.56) 0.089
0.87 - 3.35) 0.121
1.39 - 5.24) 0.003 
0.96 - 2.86) 0.068
0.70 - 2.24) 0.452
ts (n 225) undergoing lower extremity bypass surgery
(DM), high sensitivity C-reactive protein (hsCRP 5
limb ischemia (CLI), and non-single segment great
nectin (HMWA) and AA race were associated with graft(
(
(
(
(
(
(
patien
ellitus
itical
dipocontrast to the median values in the present study, which
istin
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May 20101158 Owens et alwere 12.9 ng/mL (15.1 ng/mL for CLI; 10.2 ng/mL for
claudicants), and only patients in the lowest 10th percentile
had values as low as those seen in the SIRCA study. It is not
currently known why these patients had such high values,
but it may relate to resistin production by vascular wall-
resident macrophages within atherosclerotic plaques.33 Re-
sistin, unlike hsCRP, has been shown to be correlated with
coronary artery calcification, a well-known marker of the
burden of atherosclerosis.32 Hence, we surmise that resistin
may reflect the total burden of atherosclerosis, whereas
CRP is most closely associated with the inflammatory ac-
tivity of the plaque.
One limitation of the present study is that we elected to
measure only one species of adiponectin, HMWA, rather
than considering the complex distribution or ratios of
specific fractions. However, recent studies have reported
that the HMWA is more relevant to the pathogenesis of
DM, obesity, metabolic syndrome, and vascular disease
than total serum adiponectin concentrations.34,35 Others
report a ratio of HMWA to total adiponectin as having a
stronger predictive ability in some populations.36 Further
investigation is required to determine the more accurate
species with regards to vein graft-related outcomes. In
addition, the association between HMWA and vein graft
outcomes is rather modest. HMWA was significant in the
full multivariate model as well as in models exhibiting more
parsimony. Nevertheless, in a sample size of 225 with 78
graft-related events, the potential for erroneous association
exists, and, therefore, these results must be interpreted with
A
HR 95% CI p-value
Resistin (ln) 1.75 (1.07 - 2.85) 0.025
CRP > 5 mg/L 2.39 (1.30 - 4.39) 0.005
HMWA (ln) 1.15 (0.84 - 1.56) 0.387
eGFR 0.99 (0.99 - 1.01) 0.797
age 1.00 (0.98 - 1.03) 0.764
DM 1.01 (0.55 - 1.86) 0.979
CLI 1.98 (0.95 - 4.10) 0.067
Fig 3. Multivariable analysis for amputation-free surv
vascular reconstruction with autogenous vein. (A) R
independently associated with loss of AFS in this coho
(HMWA), estimated glomerular filtration rate (eGFR), a
(B) In the diabetic-restricted cohort (n  117), only rescaution. Clearly, larger investigations are needed to corrob-orate the present findings. As with hsCRP and other bi-
omarkers, a potential causal relationship between plasma
adipokine levels and graft or other vascular events remains
speculative at the present time.
CONCLUSIONS
HMWA and resistin are novel adipokines that have
apparent clinical implications in patients undergoing pe-
ripheral vascular reconstruction. HMWA is associated with
insulin resistance and to the development of vein graft
stenosis, whereas resistin is a marker of inflammation with
clinical predictive ability for AFS in both diabetics and
nondiabetics, independent of hsCRP.
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